AR095365A1 - Procedimiento para preparar compuestos benzoxazepina - Google Patents
Procedimiento para preparar compuestos benzoxazepinaInfo
- Publication number
- AR095365A1 AR095365A1 ARP140100904A ARP140100904A AR095365A1 AR 095365 A1 AR095365 A1 AR 095365A1 AR P140100904 A ARP140100904 A AR P140100904A AR P140100904 A ARP140100904 A AR P140100904A AR 095365 A1 AR095365 A1 AR 095365A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- reacting
- forming
- prepare
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Procedimiento para preparar 2-(4-(2-(1-isopropil-3-metil-1H-1,2,4-triazo1-5-il)-5,6-dihidrobenzo[f]imidazo[1,2-d][1,4]oxazepín-9-il)-1H-pirazol-1-il)-2-metilpropanamida I, que presenta la estructura de fórmula (1) y estereoisómeros, isómeros geométricos, tautómeros y sales farmacéuticamente aceptables de los mismos, comprendiendo: (a) hacer reaccionar el compuesto de fórmula (4) y 4,4,4,4,5,5,5,5-octametil-2,2-bi(1,3,2-dioxaborolano), formando el compuesto de fórmula (5); (b) hacer reaccionar el compuesto de fórmula (5), un catalizador de paladio, y un compuesto de fórmula (3), formando el compuesto de fórmula (6); (c) hacer reaccionar el compuesto de fórmula (6) con un reactivo básico acuoso, formando el compuesto de fórmula (2); (d) hace reaccionar el compuesto de fórmula (2) con un reactivo activador de acilo, seguido de amonio, proporcionando el compuesto de fórmula (1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779619P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095365A1 true AR095365A1 (es) | 2015-10-14 |
Family
ID=50241450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100904A AR095365A1 (es) | 2013-03-13 | 2014-03-12 | Procedimiento para preparar compuestos benzoxazepina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9303043B2 (es) |
| EP (3) | EP3404032A3 (es) |
| JP (6) | JP6363120B2 (es) |
| KR (3) | KR101871133B1 (es) |
| CN (2) | CN108929333A (es) |
| AR (1) | AR095365A1 (es) |
| AU (3) | AU2014230812B2 (es) |
| BR (1) | BR112015020716A2 (es) |
| CA (6) | CA3005118A1 (es) |
| HK (1) | HK1215433A1 (es) |
| IL (1) | IL240793A0 (es) |
| MX (1) | MX2015011438A (es) |
| NZ (1) | NZ711192A (es) |
| RU (2) | RU2018109979A (es) |
| SG (2) | SG10201706760YA (es) |
| WO (1) | WO2014140073A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201731852A (zh) | 2013-12-16 | 2017-09-16 | 赫孚孟拉羅股份公司 | ２-（４-（２-（１-異丙基-３-甲基-１ｈ-１，２，４-三唑-５-基）-５，６-二氫苯并［ｆ］咪唑并［１，２-ｄ］［１，４］氧氮呯-９-基）-１ｈ-吡唑-１-基）-２-甲基丙醯胺之多晶型、製造方法及醫藥用途 |
| SI3317284T1 (sl) | 2015-07-02 | 2020-02-28 | F. Hoffmann-La Roche Ag | Spojine benzoksazepin oksazolidinona in načini uporabe |
| CN111848643A (zh) | 2015-07-02 | 2020-10-30 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 |
| CN105906635A (zh) * | 2016-06-08 | 2016-08-31 | 上海大学 | 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法 |
| RU2736722C2 (ru) * | 2016-07-29 | 2020-11-19 | Джапан Тобакко Инк. | Способ получения соединения пиразоламида |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| AR110527A1 (es) | 2016-12-15 | 2019-04-10 | Hoffmann La Roche | Proceso para la preparación de compuestos de benzoxazepina oxazolidinona |
| CN108752237A (zh) * | 2018-07-05 | 2018-11-06 | 四川青木制药有限公司 | 一种对氨基苯甲脒盐酸盐的新制备方法 |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
| US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| WO2000024720A1 (en) * | 1998-10-23 | 2000-05-04 | Dow Agrosciences Llc | 3-(substituted phenyl)-5-(substituted cyclopropyl)-1,2,4-triazole compounds |
| US8828902B2 (en) | 2001-07-12 | 2014-09-09 | Reaxa Limited | Microencapsulated catalyst methods of preparation and method of use thereof |
| US20050014805A1 (en) * | 2001-10-12 | 2005-01-20 | Chenzhi Zhang | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity |
| JP5116687B2 (ja) | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤 |
| JP2010507577A (ja) | 2006-10-23 | 2010-03-11 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | トリアゾロピリダジンタンパク質キナーゼモジュレーター |
| AU2007309149C1 (en) * | 2006-10-23 | 2013-04-04 | Sgx Pharmaceuticals, Inc. | Bicyclic triazoles as protein kinase modulators |
| WO2008088881A1 (en) | 2007-01-19 | 2008-07-24 | Xcovery, Inc. | Kinase inhibitor compounds |
| ES2439705T3 (es) * | 2007-10-25 | 2014-01-24 | Genentech, Inc. | Proceso para la preparación de compuestos de tienopirimidina |
| WO2009105500A1 (en) * | 2008-02-21 | 2009-08-27 | Schering Corporation | Compounds that are erk inhibitors |
| EP2276767B1 (en) | 2008-03-31 | 2014-05-07 | Genentech, Inc. | Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| BR112012006802A2 (pt) | 2009-09-28 | 2020-08-18 | F.Hoffmann-La Roche Ag | composto, composição farmacêutica, método para tratar câncer, usos de um composto, kit e invenção |
| NZ597833A (en) | 2009-09-28 | 2014-01-31 | Hoffmann La Roche | Benzoxazepin pi3k inhibitor compounds and methods of use |
| EP2493307B1 (en) * | 2009-10-29 | 2016-04-27 | Merck Sharp & Dohme Corp. | Bridged bicyclic piperidine derivatives and methods of use thereof |
| CN102558167A (zh) * | 2010-12-29 | 2012-07-11 | 中国医学科学院药物研究所 | Gk和ppar双重激动活性的噻唑烷二酮衍生物 |
| MX340013B (es) * | 2011-03-21 | 2016-06-22 | Hoffmann La Roche | Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso. |
| NO3175985T3 (es) * | 2011-07-01 | 2018-04-28 | ||
| KR101909801B1 (ko) * | 2012-06-08 | 2018-10-18 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물 |
-
2014
- 2014-03-12 CA CA3005118A patent/CA3005118A1/en not_active Abandoned
- 2014-03-12 BR BR112015020716A patent/BR112015020716A2/pt not_active Application Discontinuation
- 2014-03-12 KR KR1020177016062A patent/KR101871133B1/ko active IP Right Grant
- 2014-03-12 EP EP18173513.5A patent/EP3404032A3/en active Pending
- 2014-03-12 SG SG10201706760YA patent/SG10201706760YA/en unknown
- 2014-03-12 SG SG11201507394RA patent/SG11201507394RA/en unknown
- 2014-03-12 JP JP2015562108A patent/JP6363120B2/ja active Active
- 2014-03-12 CA CA2948765A patent/CA2948765A1/en not_active Abandoned
- 2014-03-12 CN CN201810489045.8A patent/CN108929333A/zh active Pending
- 2014-03-12 EP EP20204345.1A patent/EP3845540A1/en active Pending
- 2014-03-12 WO PCT/EP2014/054786 patent/WO2014140073A1/en active Application Filing
- 2014-03-12 AR ARP140100904A patent/AR095365A1/es unknown
- 2014-03-12 CA CA2948763A patent/CA2948763C/en not_active Expired - Fee Related
- 2014-03-12 KR KR1020187016976A patent/KR20180070715A/ko not_active Application Discontinuation
- 2014-03-12 US US14/205,634 patent/US9303043B2/en active Active
- 2014-03-12 CA CA3005112A patent/CA3005112A1/en not_active Abandoned
- 2014-03-12 RU RU2018109979A patent/RU2018109979A/ru not_active Application Discontinuation
- 2014-03-12 CA CA3005103A patent/CA3005103A1/en not_active Abandoned
- 2014-03-12 EP EP14709314.0A patent/EP2970329A1/en not_active Withdrawn
- 2014-03-12 KR KR1020157024484A patent/KR101821468B1/ko active IP Right Grant
- 2014-03-12 RU RU2015138488A patent/RU2649976C2/ru not_active IP Right Cessation
- 2014-03-12 MX MX2015011438A patent/MX2015011438A/es unknown
- 2014-03-12 NZ NZ711192A patent/NZ711192A/en not_active IP Right Cessation
- 2014-03-12 AU AU2014230812A patent/AU2014230812B2/en not_active Ceased
- 2014-03-12 CA CA2897618A patent/CA2897618A1/en not_active Abandoned
- 2014-03-12 CN CN201480015055.8A patent/CN105377856B/zh active Active
-
2015
- 2015-08-24 IL IL240793A patent/IL240793A0/en unknown
-
2016
- 2016-03-23 HK HK16103386.8A patent/HK1215433A1/zh unknown
- 2016-06-28 AU AU2016204432A patent/AU2016204432B2/en not_active Ceased
-
2017
- 2017-07-10 JP JP2017135083A patent/JP6442005B2/ja active Active
-
2018
- 2018-02-27 AU AU2018201393A patent/AU2018201393A1/en not_active Abandoned
- 2018-03-12 JP JP2018044050A patent/JP2018150298A/ja active Pending
- 2018-08-16 JP JP2018153231A patent/JP6663459B2/ja active Active
- 2018-11-22 JP JP2018219226A patent/JP2019089762A/ja active Pending
-
2020
- 2020-02-28 JP JP2020032846A patent/JP2020114814A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095365A1 (es) | Procedimiento para preparar compuestos benzoxazepina | |
| AR092960A1 (es) | Procedimiento para preparar compuestos tienopirimidina | |
| BR112014030365A2 (pt) | síntese de composto antiviral | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| AR083797A1 (es) | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos | |
| CU24354B1 (es) | Procedimiento de obtención de derivados de tetrafluoropropilmorfolina | |
| UY32296A (es) | Nuevos compuestos | |
| ECSP15006871A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| BR112018015880A2 (pt) | forma cristalina a de agonista de tlr7, método de preparação e uso da mesma | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| ECSP13012914A (es) | Síntesis de derivados de 2-carboxamida-cicloamino-urea | |
| BR112016022437A2 (pt) | Processo para preparação de (2s,5r)-6-(benziloxi)-7-oxo-1,6- diazabiciclo[3,2,1]octano-2-carboxilato de sódio | |
| BR112016009665A8 (pt) | polimorfos, composição farmacêutica, processos para a preparação de um polimorfo e usos dos polimorfos | |
| CR20150160A (es) | Derivados de macrólidos, su preparación y su uso terapéutico | |
| CY1120482T1 (el) | Μεθοδος συνθεσης 3,4-διμεθοξυδικυκλο[4.2.0]οκτα-1,3,5-τριενο-7-καρβονιτριλιου και εφαρμογη στη συνθεση της ιβαμπραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξy | |
| BR112015030589A2 (pt) | formas polimórficas de fosfato de icotinibe e seus usos | |
| BR112014000613A2 (pt) | método para a preparação de ácido ciclo-hexanocarboxílico | |
| CY1117315T1 (el) | Νεα μεθοδος συνθεσης του 3-(2-βρωμο-4,5-διμεθοξυφαινυλ)προπανονιτριλιου και εφαρμογη στη συνθεση της ιβαμπραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ | |
| JO3132B1 (ar) | عملية تخليق مركبات 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one واستخدامها لإعداد ايفابرادين | |
| BR112012010484A2 (pt) | processo para preparar compostos da fórmula i, composto e processo para prepapar compostos de pirazol 1,3 dissubstituídos da fórmula vi. | |
| PL414008A1 (pl) | Nowe pochodne chinolizydyny i sposób otrzymywania nowych pochodnych chinolizydyny | |
| BR112014007547A2 (pt) | método para produzir de derivados de 3,4-dihidroisoquinolina e intermediários de produção da mesma | |
| CO6650412A2 (es) | Proceso para la preparación de 8-alcoxi[1.2.4]triazol[1.5-c]pirimidin-2-aminas substituidas -5 | |
| PL414012A1 (pl) | Nowe pochodne indolizydyny i sposób otrzymywania nowych pochodnych indolizydyny |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |